Pegylated interferon-{alpha}-2b reduces corticosteroid requirement in patients with Behcet's disease with upregulation of circulating regulatory T cells and reduction of Th17
Conclusions
The addition of peginterferon-α-2b to the drug regime of BD patients did not significantly reduce their corticosteroid dose required at 1 year. However, in those on corticosteroids at baseline post hoc analysis demonstrated that the addition of peginterferon-α-2b did result in a significant reduction in corticosteroid dose with a significantly improved quality of life and trend to reduce other required immunosuppressive agents. This effect was seen at 1 year and associated with a rise in Tregs suggesting a possible mode for interferon action.
Trial registration number
ISRCTN 36354474; EudraCT 2004-004301-18.
Source: Annals of the Rheumatic Diseases - Category: Rheumatology Authors: Lightman, S., Taylor, S. R. J., Bunce, C., Longhurst, H., Lynn, W., Moots, R., Stanford, M., Tomkins-Netzer, O., Yang, D., Calder, V. L., Haskard, D. O. Tags: Immunology (including allergy), Ophthalmology, Drugs: musculoskeletal and joint diseases, Vascularitis Clinical and epidemiological research Source Type: research
More News: Allergy | Allergy & Immunology | Behcet's Disease | Corticosteroid Therapy | Epidemiology | Opthalmology | Rheumatology